PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN) today announced The Journal of Urology ® published results from the Phase 2b OPTIMA II trial, a Phase 2b, open-label, single-arm ...

(RTTNews) - UroGen Pharma Ltd. (URGN), a biotech company focused on urothelial and specialty cancers, announced on Wednesday that long-term follow-up data from the OLYMPUS trial of JELMYTO or ...

In recent years, clinical trial reports in major urology journals have been more likely to include data on harmful effects of treatments, reports a study in the January issue of The Journal of Urology ...

Levee Medical(R) , a medical device company focused on improving outcomes for prostate cancer surgery patients, today announced continued progress in the clinical and commercial advancement of its ...

In a randomized trial of men with a single suspicious lesion on MRI, targeted perilesional biopsy matched standard targeted and systematic biopsy for detecting clinically significant prostate cancer - ...

An article published in the Journal of Urology is reporting on the first 19 humans treated with a new non-invasive method designed to break up kidney stones using sound waves. The method, dubbed burst ...

ENVISION Reports 79.6% Complete Response Rate at 3 Months, 82.3% Duration of Response at 12 Months, and Consistent Safety Profile UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to ...

October 28, 2022 – The standard cutoff point for low testosterone levels may not be accurate for men in their mid-forties and younger, reports a study in The Journal of Urology®, an Official Journal ...

September 11, 2024 — A noninvasive ultrasound technology called Break Wave™ lithotripsy (BWL) offers a safe and effective new option for treatment of urinary stones, reports a clinical trial in the ...

Artificial urinary sphincter implantation is an effective option with an acceptable complication rate for moderate to severe stress urinary incontinence.

Levee Medical®, a medical device company focused on improving outcomes for prostate cancer surgery patients, today announced continued progress in the clinical and commercial advancement of its Voro® ...